Results 191 to 200 of about 15,799 (221)

Evolution of HCV NS5B Non-nucleoside Inhibitors

2019
The HCV polymerase NS5B is susceptible to allosteric inhibition at four sites that have been exploited by compounds that have shown clinical efficacy. The history of the discovery and optimization of leads acting at each of these sites is discussed. The many clinical candidates that emerged from these efforts are described, together with their impact ...
openaire   +1 more source

HCV NS5B Inhibitor PSI-6130

Synfacts, 2010
openaire   +1 more source

Synthesis of NS5B Polymerase Inhibitor GSK852A

Synfacts, 2015
openaire   +1 more source

2-Heteroarylimino-5-arylidene-4-thiazolidinones as a new class of non-nucleoside inhibitors of HCV NS5B polymerase

European Journal of Medicinal Chemistry, 2013
İlkay Küçükgüzel, Esra Tatar, Tanaji T Talele   +2 more
exaly  

Novel thiazolones as HCV NS5B polymerase allosteric inhibitors: Further designs, SAR, and X-ray complex structure

Bioorganic and Medicinal Chemistry Letters, 2007
Shunqi Yan
exaly  

I. Novel HCV NS5B polymerase inhibitors: Discovery of indole 2-carboxylic acids with C3-heterocycles

Bioorganic and Medicinal Chemistry Letters, 2011
Charles A Lesburg, Jose Duca
exaly  

Discovery of new scaffolds for rational design of HCV NS5B polymerase inhibitors

European Journal of Medicinal Chemistry, 2012
Volodymyr G. Bdzhola, Jin-Ching Lee, Tanaji T Talele   +2 more
exaly  

HCV non-structural protein 5B (NS5B)

Science-Business eXchange, 2010
openaire   +1 more source

Structure–activity relationship (SAR) studies of quinoxalines as novel HCV NS5B RNA-dependent RNA polymerase inhibitors

Bioorganic and Medicinal Chemistry Letters, 2007
Shunqi Yan
exaly  

Inhibition of hepatitis C virus NS5B polymerase by S-trityl-l-cysteine derivatives

European Journal of Medicinal Chemistry, 2012
Jin-Ching Lee, Naoya Sakamoto, Benoit Joseph   +2 more
exaly